1. Scrip
  2. >>Business
  3. >>Deals

Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes

 
• By Joseph Haas

ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Alkermes PLC has signed the most obvious partner for its late-stage multiple sclerosis drug, Biogen Inc., in a deal that seems advantageous to both companies. The Phase III next-generation fumarate ALKS 8700 could offer potential tolerability advantages compared to Biogen's currently marketed Tecfidera (dimethyl fumarate) and importantly is patent protected until 2033.

Thus, the deal announced Nov

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.